Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T18:56:33.060Z.
Calculation as of: 2026-10-06T18:56:33.060Z.
Quote observation: 2026-10-06T18:55:15.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 6caa0376099c5ebdf209f9b018955c4d65987c3db8176dc1b5ff0a1c5aca19bf
PE RATIO
N/A
Market Cap
$472.71M
PE Ratio
N/A
TTM Avg
16.90
3Y Avg
16.90
5Y Avg
16.90
Market Cap
$488.68M
PE Ratio
18.60
TTM Avg
12.02
3Y Avg
15.67
5Y Avg
102.65
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Bright Minds Biosciences Inc. (DRUG) | $474.37M | N/A | N/A | N/A | N/A |
| Kamada Ltd. (KMDA)vs › | $471.36M | 21.56 | 21.78 | 26.84 | 31.34 |
| Alpha Teknova, Inc. (TKNO)vs › | $474.22M | N/A | 1146.36 | 1146.36 | 1146.36 |
| Cerus Corporation (CERS)vs › | $474.59M | N/A | 20.76 | 20.76 | 20.76 |
| Arvinas, Inc. (ARVN)vs › | $474.91M | 46.00 | 54.09 | 54.09 | 54.09 |
| Contineum Therapeutics, Inc. (CTNM)vs › | $472.71M | N/A | 16.90 | 16.90 | 16.90 |
| Sight Sciences, Inc. (SGHT)vs › | $469.56M | N/A | N/A | N/A | N/A |
| Evolus, Inc. (EOLS)vs › | $486.67M | N/A | N/A | N/A | N/A |
| Puma Biotechnology, Inc. (PBYI)vs › | $488.68M | 18.60 | 12.02 | 15.67 | 102.65 |
| NRC Health (NRC)vs › | $455.92M | 80.15 | 41.70 | 28.27 | 29.07 |
Trailing P/E
N/A
Forward P/E
N/A
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
